Ergot alkaloids constitute one of the oldest and most structurally distinctive drug classes in pharmacology, with a history that stretches from medieval mass poisoning epidemics to the modern treatment of migraine, hyperprolactinemia, Parkinson's disease, and postpartum hemorrhage. The entire pharmacological diversity of this class traces to a single fungal organism and a single chemical scaffold: the lysergic acid tetracyclic ring system produced by Claviceps purpurea.
The ergot fungus Claviceps purpurea is an obligate parasite of cereal grasses, most commonly rye (Secale cereale), although it also infects wheat, barley, and wild grasses. The organism infects the ovary of the host plant, replacing the developing grain with a hard, dark, curved mass called the sclerotium, which is the ergot body from which the alkaloids are extracted. The sclerotium contains a complex mixture of ergot alkaloids, with the specific composition varying by fungal strain, host plant, and environmental conditions. Historical outbreaks of ergotism, caused by consumption of ergot-contaminated grain, produced two distinct clinical syndromes: the gangrenous form, in which intense peripheral vasoconstriction led to dry gangrene of the extremities, and the convulsive form, characterized by seizures, hallucinations, and psychiatric disturbances. The gangrenous form was known historically as St. Anthony's Fire because pilgrimage to the shrine of St. Anthony in France, which passed through regions with uncontaminated grain supplies, was associated with spontaneous recovery as victims left the contaminated food source behind.1
The chemical architecture of ergot alkaloids is built on the tetracyclic ergoline ring system, a rigid, planar structure composed of a benzene ring fused to a pyrrole ring, an additional six-membered ring containing nitrogen, and a final six-membered ring. The core scaffold is lysergic acid, which contains a carboxyl group at the C-8 position and a double bond between C-9 and C-10. All pharmacologically active natural ergot alkaloids are amide derivatives of lysergic acid, in which the carboxyl group is condensed with various amino acid or peptide substituents. The stereochemistry of the C-5 and C-8 positions is critical for receptor binding: the natural d-isomer (8-beta configuration) is pharmacologically active, while the iso-ergot alkaloids (8-alpha configuration, designated with the prefix "ergo" reversed as iso-) are substantially less potent and are generally considered pharmacologically inactive at the relevant clinical receptors.5
Ergot alkaloids are classified into three principal chemical subgroups based on the nature of the substituent attached to the C-8 carboxyl of lysergic acid. The clavine alkaloids, such as agroclavine and elymoclavine, are the biosynthetically earliest group and retain the ergoline ring without an amide substituent; they have limited direct clinical application but are biosynthetic precursors. The lysergic acid amides, the simplest group, include ergine (d-lysergic acid amide) and the semisynthetic lysergic acid diethylamide (LSD); these are primarily of toxicological and neuropharmacological interest rather than therapeutic use. The peptide ergot alkaloids, also called ergopeptines, are the clinically dominant group: natural ergopeptines include ergotamine, ergocristine, ergocornine, ergocryptine, and ergonovine (ergometrine), while semisynthetic derivatives include dihydroergotamine (DHE), bromocriptine, cabergoline, pergolide, and methysergide. The peptide alkaloids are characterized by a tripeptide moiety attached at C-8, forming a bicyclic ring structure known as the cyclol, which contributes substantially to receptor selectivity.1
Natural ergot alkaloids (ergotamine, ergonovine) are extracted directly from Claviceps purpurea cultures or synthesized from lysergic acid. Semisynthetic derivatives (dihydroergotamine, bromocriptine, cabergoline, methysergide) are produced by chemical modification of the natural scaffold, typically at the C-9/C-10 double bond (hydrogenation to produce dihydro derivatives) or at the peptide substituent. Hydrogenation at C-9/C-10 reduces arterial vasoconstrictive potency while preserving or enhancing venous and alpha-adrenergic activity, which is why dihydroergotamine has a more favorable vascular safety profile than ergotamine in migraine treatment. Modification of the peptide substituent is responsible for the dramatically different receptor selectivity profiles seen across the semisynthetic series: bromocriptine and cabergoline are highly selective dopamine D2 agonists, while methysergide is primarily a serotonin antagonist.
The biosynthetic pathway of ergot alkaloids in Claviceps purpurea begins with the prenylation of tryptophan, proceeds through a series of oxidative cyclization steps to form the ergoline ring system, and culminates in the assembly of the peptide substituent from three amino acid residues (proline and two others that vary by alkaloid). The gene cluster responsible for ergot alkaloid biosynthesis (the EAS cluster) has been extensively characterized and encodes the enzymes for all steps from tryptophan to the final ergopeptine product. Understanding the biosynthetic pathway has enabled the development of fermentation-based production systems for lysergic acid, which serves as the starting material for all semisynthetic derivatives currently in clinical use. The stereochemical control required for pharmacologically active configurations is maintained throughout biosynthesis by substrate-specific enzymes, and commercial semisynthesis replicates this stereochemical selectivity through chiral catalysis and resolution steps.2
No other drug class in clinical pharmacology binds productively to as many receptor families simultaneously as the ergot alkaloids. A single compound such as ergotamine interacts with alpha-1 and alpha-2 adrenergic receptors, dopamine D2 receptors, and multiple serotonin receptor subtypes, acting as a partial agonist or partial antagonist at each, with the net clinical effect determined by which receptor population predominates in the target tissue at the time of drug exposure. This multi-receptor promiscuity is not pharmacological noise; it is the mechanistic basis of both the therapeutic versatility and the complex toxicology of the class.
Alpha-adrenergic receptor interactions are central to the vasoactive and uterotonic effects of most ergot alkaloids. Ergotamine and its natural congeners act as partial agonists at both alpha-1 and alpha-2 adrenergic receptors. Alpha-1 adrenergic receptors (alpha-1 ARs) are coupled to Gq proteins and mediate smooth muscle contraction through phospholipase C activation, inositol trisphosphate generation, and intracellular calcium release; their activation by ergot alkaloids contributes to arterial vasoconstriction and uterine contraction. Alpha-2 adrenergic receptors (alpha-2 ARs) are coupled to Gi proteins and are located both postsynaptically (where they also mediate smooth muscle contraction in some vascular beds) and presynaptically (where they function as autoreceptors, inhibiting further norepinephrine release). Ergot alkaloid activation of presynaptic alpha-2 ARs can paradoxically limit the magnitude of the vasoconstrictive response by reducing endogenous norepinephrine release, a negative feedback interaction that partially attenuates the pressor response seen with some natural ergopeptines.3
Dopamine D2 receptor agonism is the pharmacological mechanism that distinguishes the semisynthetic dopaminergic ergot derivatives from the natural alkaloids. Dopamine D2 receptors are G protein-coupled receptors linked to Gi, which inhibits adenylyl cyclase, reduces cyclic adenosine monophosphate (cAMP) production, and suppresses cellular activity in D2-expressing tissues. In the anterior pituitary, D2 receptor activation on lactotroph cells inhibits prolactin synthesis and secretion, which is the basis for the therapeutic use of bromocriptine and cabergoline in hyperprolactinemia and prolactinoma. In the nigrostriatal and mesolimbic dopamine pathways of the central nervous system (CNS), D2 agonism produces the antiparkinsonian and neuropsychiatric effects seen with dopaminergic ergots. The natural ergopeptines ergotamine and ergonovine also bind D2 receptors but with substantially lower affinity and selectivity than the semisynthetic dopaminergic derivatives; their clinical effects are dominated by their adrenergic and serotonergic actions.4
Serotonin receptor interactions of ergot alkaloids are pharmacologically heterogeneous and clinically important. The serotonin receptor family comprises at least 14 distinct subtypes organized into seven families (5-HT1 through 5-HT7). Ergot alkaloids interact productively with several of these subtypes. At 5-HT1B and 5-HT1D receptors, ergotamine and dihydroergotamine (DHE) act as agonists; 5-HT1B receptors on cranial blood vessel smooth muscle mediate vasoconstriction, and 5-HT1D receptors on trigeminal nerve terminals inhibit the release of vasoactive neuropeptides, both mechanisms contributing to antimigraine efficacy. At 5-HT2A receptors, ergot alkaloids act as partial agonists in vascular smooth muscle, contributing to vasoconstriction through a pathway distinct from adrenergic activation. Methysergide, a semisynthetic ergot derivative, acts primarily as a 5-HT2A and 5-HT2C antagonist, which is the mechanistic basis of its (now largely historical) use in migraine prophylaxis.5 The complex interplay among these serotonergic effects means that the net vascular response to an ergot alkaloid depends on the relative expression of 5-HT1 versus 5-HT2 receptor subtypes in the target vascular bed.
Ergotamine: high affinity for alpha-1/alpha-2 adrenergic, 5-HT1B/1D (agonist), 5-HT2A (partial agonist), D2 (weak). Dihydroergotamine (DHE): reduced arterial alpha-1 activity vs. ergotamine; retained 5-HT1B/1D agonism; enhanced venous alpha-adrenergic activity. Bromocriptine: high D2 agonism; partial 5-HT1 agonism; alpha-adrenergic antagonism at therapeutic doses. Cabergoline: very high D2 selectivity; 5-HT2B agonism at high doses (cardiac valvulopathy mechanism). Methysergide: 5-HT2A/2C antagonism; weak 5-HT1 agonism; minimal adrenergic activity. Ergonovine (ergometrine): alpha-adrenergic partial agonism; 5-HT2 agonism; weak D2 activity. The pattern across the series reflects how structural modification of the peptide substituent systematically shifts receptor selectivity.
The concept of functional selectivity, also called biased agonism, is relevant to understanding ergot alkaloid receptor pharmacology. At a given receptor, different ligands can stabilize distinct receptor conformations that preferentially couple to different downstream signaling pathways. Ergot alkaloids, as partial agonists at multiple receptor subtypes, do not simply activate or block receptors in a binary fashion; they stabilize receptor states that may couple differentially to G protein versus beta-arrestin pathways, producing qualitatively different cellular responses than full agonists at the same receptor. This concept has been invoked to explain why ergot alkaloids sometimes produce vasoconstrictive effects that are qualitatively different from those of endogenous catecholamines or serotonin acting at the same receptors, and why their toxicological profile, particularly the sustained vasospasm seen in ergotism, cannot be fully explained by simple receptor occupancy models alone.3
The vascular effects of ergot alkaloids are both their most therapeutically exploited property and the source of their most serious toxicity. The distinction between therapeutic vasoconstriction in cranial vessels and pathological vasospasm in peripheral and coronary vessels is not merely a matter of dose; it reflects genuine differences in receptor expression, vascular tone at baseline, and the pharmacokinetic behavior of individual alkaloids in different vascular compartments.
Arterial vasoconstriction by ergot alkaloids is mediated through three parallel receptor mechanisms that converge on smooth muscle contraction. Alpha-1 adrenergic receptor (alpha-1 AR) activation initiates the Gq/phospholipase C (PLC)/inositol trisphosphate (IP3) cascade, releasing calcium from the sarcoplasmic reticulum and activating myosin light chain kinase (MLCK), producing sustained contraction. Concurrent activation of 5-HT2A receptors amplifies this response through an independent Gq-coupled mechanism, and 5-HT1B receptor activation on smooth muscle contributes additional contractile drive in cranial vessels. The combination of these three mechanisms acting simultaneously means that ergot alkaloid-induced vasoconstriction is not fully reversible by blocking any single receptor pathway; complete reversal typically requires a vasodilatory intervention that operates downstream of receptor activation, such as nitroprusside or calcium channel blockade, which is why ergot-induced peripheral vasospasm is a medical emergency that may not respond to receptor antagonists alone.5
The cranial vasculature, particularly the dural and pial arteries that supply the meningeal structures implicated in migraine pathophysiology, expresses a high density of 5-HT1B receptors relative to peripheral muscular arteries. This differential receptor expression provides the pharmacological basis for the cranioselective vasoconstriction produced by 5-HT1B/1D agonists, including triptans and, to a lesser extent, ergotamine and DHE. However, ergot alkaloids are substantially less cranioselective than triptans because they also activate alpha-1 ARs and 5-HT2A receptors, which are expressed in peripheral vascular beds including coronary arteries, digital arteries, and mesenteric vessels. This lack of vascular selectivity is the mechanistic reason why ergotamine and DHE are contraindicated in patients with coronary artery disease, peripheral vascular disease, and cerebrovascular disease, and why careful patient selection is mandatory when these agents are used therapeutically.6
Venous pharmacology of ergot alkaloids, particularly DHE, is clinically distinct from arterial pharmacology and has been proposed as a mechanism contributing to antimigraine efficacy independent of arterial vasoconstriction. DHE has substantially greater potency at venous alpha-adrenergic receptors than at arterial smooth muscle relative to ergotamine, an effect attributed to enhanced alpha-2 AR postsynaptic activity and venous smooth muscle sensitivity following hydrogenation of the C-9/C-10 double bond. Venoconstriction reduces venous capacitance and increases venous return, which activates baroreceptors and reflexively reduces sympathetic outflow; this systemic hemodynamic effect has been proposed to contribute to the relief of the throbbing vascular headache component of migraine through a mechanism distinct from direct cranial arterial constriction. DHE also reduces plasma extravasation from dural vessels and inhibits the release of calcitonin gene-related peptide (CGRP) from trigeminal nerve terminals, anti-inflammatory mechanisms that are shared with the triptan class.5
Ergot-induced vasospasm in coronary and peripheral arteries represents the same receptor-mediated mechanism as therapeutic cranial vasoconstriction, occurring in vascular beds where that effect is harmful rather than beneficial. Coronary vasospasm producing angina or myocardial infarction has been reported with both ergotamine and DHE, most commonly in the setting of CYP3A4 inhibitor co-administration (macrolides, azole antifungals, HIV protease inhibitors) that dramatically elevates ergot plasma concentrations. Peripheral vasospasm presents as cold, mottled, pulseless extremities with pain; if sustained, it progresses to ischemic necrosis and gangrene. Treatment requires reversal of any pharmacokinetic precipitant, intravenous vasodilators (nitroprusside, prostaglandin E1), anticoagulation, and in refractory cases regional anesthetic sympathetic blockade. Alpha-adrenergic antagonists (phentolamine) provide partial relief by blocking alpha-1 and alpha-2 AR mediated components but do not address the 5-HT2A component of the spasm.
The duration of ergot alkaloid-induced vasoconstriction substantially exceeds the plasma half-life of the parent compound, a pharmacodynamic dissociation that has important clinical implications. Ergotamine has a plasma half-life of approximately 2 hours following oral administration, yet vasoconstrictive effects persist for 24 hours or longer. This prolonged effect reflects several mechanisms: slow dissociation from receptor-bound states (high receptor affinity and low off-rate kinetics), active vasoconstriction maintained by active metabolites (particularly the O-demethylated metabolite of ergotamine), and the self-sustaining nature of smooth muscle contraction once initiated, which can be maintained by calcium influx independent of continued receptor occupancy. The practical consequence is that a patient who develops ergot-induced vasospasm will not recover simply by discontinuing the drug; active vasodilatory treatment is required, and the duration of treatment must account for the prolonged pharmacodynamic effect rather than the pharmacokinetic half-life alone.5
The uterotonic action of ergot alkaloids is one of the earliest recognized pharmacological effects of the class and remains clinically relevant in the management of postpartum hemorrhage. The mechanisms responsible for uterine smooth muscle contraction overlap substantially with those governing vascular smooth muscle contraction, but the uterus adds a dimension of hormonal sensitivity that modifies the ergot response in ways that have direct clinical consequences.
Uterine smooth muscle, like vascular smooth muscle, is a target for both alpha-adrenergic and serotonergic ergot alkaloid actions. Alpha-1 adrenergic receptor (alpha-1 AR) activation in myometrial smooth muscle triggers the same Gq/PLC/IP3/calcium cascade that drives vascular contraction, producing sustained myometrial contraction. The 5-HT2A receptor-mediated component also contributes, as myometrial 5-HT2A receptor expression is upregulated by estrogen, which explains why the uterotonic response to ergot alkaloids is substantially more potent in the estrogen-primed uterus of a pregnant or recently postpartum patient than in the non-pregnant uterus. This hormonal sensitization is pharmacologically significant: doses of ergotamine or ergonovine (ergometrine) that produce modest vasoconstriction in non-pregnant patients can elicit intense, sustained tetanic uterine contractions in pregnant patients, which is the mechanistic basis for the absolute contraindication of ergot alkaloids in pregnancy beyond the immediate postpartum period used for hemorrhage control.7
Among the ergot alkaloids used clinically for uterotonic purposes, ergonovine (known as ergometrine outside North America) and its semisynthetic derivative methylergonovine (methylergometrine) are the primary agents. These compounds differ structurally from the peptide ergopeptines in that they carry a simple amide substituent (1-amino-2-propanol for ergonovine; d-lysergic acid methylamide for the active moiety of methylergonovine) rather than a complex tripeptide, which confers greater water solubility, more rapid onset, and a somewhat reduced peripheral vasoconstrictive profile relative to ergotamine. Methylergonovine is the form available in the United States (as Methergine), while ergonovine maleate is available in other countries. Both agents produce intense, prolonged uterine contractions through alpha-adrenergic and 5-HT2 receptor activation, with onset within 2–5 minutes of intramuscular injection and a duration of action of 3–6 hours.8
The uterotonic response to ergot alkaloids differs qualitatively from that produced by oxytocin, the other primary uterotonic agent used in obstetric practice. Oxytocin acts via Gq-coupled oxytocin receptors to produce rhythmic, coordinated, wave-like contractions that mimic physiological labor contractions; its effect is frequency- and amplitude-modulated and is highly dependent on the density of uterine oxytocin receptors, which increases dramatically at term and in the early postpartum period. Ergot alkaloids, in contrast, produce tonic, sustained, non-rhythmic contractions through their combined alpha-adrenergic and serotonergic actions. This tonic contraction pattern is effective at compressing the myometrial vasculature and controlling postpartum hemorrhage (PPH) by a mechanical tamponade mechanism, but it is inappropriate during active labor because sustained tonic contraction compresses the placental vascular bed and can cause fetal hypoxia. This distinction explains why ergot alkaloids are restricted to the postpartum setting and are never used for labor induction or augmentation.7
In the management of postpartum hemorrhage (PPH), ergot alkaloids occupy a specific clinical niche. Oxytocin remains the first-line uterotonic agent because it is effective, has rapid onset, and lacks the vasoconstrictive side effects that limit ergot use. Methylergonovine 0.2 mg intramuscularly is added as second-line therapy when oxytocin alone is insufficient, with the important caveat that it is contraindicated in hypertension and preeclampsia because the alpha-adrenergic vasoconstriction that accompanies uterine contraction can precipitate hypertensive crisis or stroke. Carboprost (15-methyl prostaglandin F2-alpha) and misoprostol (prostaglandin E1 analog) are alternative second-line agents without the vasoconstrictive contraindication. The choice among uterotonic agents in PPH is therefore driven primarily by the patient's blood pressure status and concurrent medications.
Systemic cardiovascular effects accompanying ergot uterotonic use are clinically meaningful even at therapeutic doses. The alpha-adrenergic vasoconstriction is not limited to the uterine vasculature; systemic arterial constriction increases peripheral vascular resistance, raising both systolic and diastolic blood pressure. In normotensive postpartum patients, this pressor response is generally well-tolerated and transient. In patients with gestational hypertension, preeclampsia, or eclampsia, however, the same pressor effect can precipitate severe hypertension, hypertensive encephalopathy, or hemorrhagic stroke. The 5-HT2A component of the vasoconstrictive response also contributes to platelet aggregation enhancement through receptor-mediated effects on platelet 5-HT2A receptors, an interaction that is pharmacologically relevant in patients with coagulation abnormalities or pre-existing thrombotic risk, though this effect is rarely dose-limiting at therapeutic methylergonovine doses.7
Partial agonism is the pharmacological concept most essential to understanding why ergot alkaloids produce different, sometimes opposite, effects depending on the tissue examined, the dose administered, the concurrent level of endogenous agonist activity, and the receptor subtype that predominates in a given vascular or smooth muscle bed. A partial agonist occupies a receptor and activates it, but produces a submaximal response even at full receptor occupancy; it also competes with full agonists for the same receptor, so that in the presence of high endogenous agonist tone, a partial agonist will displace the full agonist and reduce the overall response below what the endogenous agonist alone would have produced.
The intrinsic efficacy of an ergot alkaloid at a given receptor, expressed as the fraction of the maximum response achievable by a full agonist at full receptor occupancy, varies substantially across receptor subtypes and across individual alkaloids. Ergotamine has an intrinsic efficacy at alpha-1 adrenergic receptors (alpha-1 ARs) of approximately 40–60% of the maximum response produced by norepinephrine, a full alpha-1 agonist. In a tissue where baseline alpha-adrenergic tone is low, such as a non-stimulated peripheral artery in a resting patient, ergotamine acts predominantly as an agonist, producing vasoconstriction. In a tissue where the sympathetic nervous system is already maximally activated, such as a mesenteric artery during hemorrhagic shock in which high circulating norepinephrine is producing near-maximal vasoconstriction, ergotamine would compete with norepinephrine for receptor occupancy and, by displacing the full agonist and substituting its lower intrinsic efficacy, would reduce the vasoconstriction below the maximum level, functioning effectively as an antagonist. This agonist-in-low-tone / antagonist-in-high-tone behavior is characteristic of all partial agonists and is not unique to ergots, but it has particular clinical relevance here because the relevant tissues (blood vessels, uterus) operate across a wide range of baseline sympathetic tone.3
The most clinically dramatic manifestation of ergot partial agonism is the vasoconstrictive response that follows intravenous ergotamine administration. When ergotamine is administered intravenously to a patient whose sympathetic tone is moderate, the drug acts as an agonist at alpha-1 and alpha-2 ARs and 5-HT2A receptors, producing vasoconstriction and an initial rise in blood pressure. The baroreceptor reflex responds to this hypertension by increasing vagal tone and reducing sympathetic outflow. As sympathetic tone falls, the pharmacological character of ergotamine at its receptors shifts from predominantly agonist toward more pronounced antagonist behavior at the adrenergic component, while the 5-HT2A agonist component remains active. The net result can be an initial pressor phase followed by a secondary vasodilatory and hypotensive phase, the so-called paradoxical hypotension after ergotamine, which led to early confusion about the drug's fundamental pharmacological character before the concept of partial agonism was established.9
Historical clinical pharmacology records document cases in which ergotamine, administered in the context of high sympathetic tone (cold exposure, severe hypertension, heavy exertion), produced transient vasodilation rather than the expected vasoconstriction. This paradoxical response reflects the partial agonist character of the drug at alpha-adrenergic receptors: when endogenous norepinephrine occupancy is high and receptors are operating near maximum, ergotamine displaces the full agonist and reduces the response. The same mechanism underlies the early therapeutic use of ergotamine and dihydroergotamine as antihypertensives in the mid-20th century, before more selective adrenergic agents became available. The lesson for contemporary practice is that ergot alkaloid vascular effects are context-dependent and cannot be predicted without considering the patient's baseline sympathetic and vascular tone.
The duration of ergot partial agonist effects at individual receptor subtypes is modulated by receptor internalization dynamics following ligand binding. Full agonist binding to G protein-coupled receptors typically triggers rapid receptor phosphorylation by G protein-coupled receptor kinases (GRKs), beta-arrestin recruitment, and receptor internalization, which terminates signaling and reduces receptor surface expression. Partial agonists such as ergot alkaloids, which stabilize distinct receptor conformations, may drive receptor internalization at different rates than full agonists, leading to complex temporal patterns of receptor desensitization and resensitization that contribute to the prolonged and variable pharmacodynamic responses seen clinically. Chronic ergotamine use in patients with frequent migraine is associated with rebound headache (medication overuse headache), a phenomenon that involves both central sensitization at trigeminal pain pathways and peripheral receptor adaptations at 5-HT1B/1D receptors, reflecting the consequence of sustained partial agonist exposure at receptors that normally undergo phasic activation by endogenous serotonin.10
The relationship between ergot alkaloid dose and pharmacological effect is non-linear in a way that directly reflects partial agonist pharmacodynamics combined with multi-receptor targeting. At low doses, ergotamine's effects are dominated by 5-HT1B/1D agonism (high-affinity receptors), producing cranial vasoconstriction with minimal peripheral effects. At intermediate doses, alpha-1 AR agonism becomes prominent, adding peripheral vasoconstriction to the cranial effect. At high doses, or in the presence of pharmacokinetic drug interactions that dramatically increase plasma concentrations, the combined alpha-adrenergic, 5-HT1, and 5-HT2A activities produce intense, multi-vascular vasoconstriction that cannot be offset by partial agonist antagonism at any single receptor type. This dose-response architecture explains why ergotamine toxicity presents so differently from therapeutic use and why the margin between the therapeutic dose window and the toxic dose range is narrow and highly variable among patients, depending on CYP3A4 metabolic capacity, concurrent medications, and baseline vascular sensitivity.6
Receptor context determines effect: ergot alkaloids behave as agonists in low-tone tissues and partial antagonists in high-tone tissues; predict the response by assessing the patient's baseline sympathetic and vascular state.
Multi-receptor binding means multi-mechanism toxicity: ergot vasospasm involves alpha-adrenergic, 5-HT1B, and 5-HT2A components simultaneously; single-receptor antagonists provide incomplete reversal.
Pharmacodynamics outlast pharmacokinetics: the vasoconstrictive effect persists long after plasma concentrations have fallen; treat the pharmacodynamic endpoint (restoration of perfusion), not the pharmacokinetic endpoint (drug elimination).
Vascular selectivity is relative, not absolute: even the most cranioselective ergot alkaloid (DHE) retains peripheral vasoconstrictive activity; cardiovascular contraindications must be applied rigorously.
Hormonal state modifies uterine response: the estrogen-primed uterus of pregnancy or the immediate postpartum period is dramatically more sensitive to ergot uterotonic effects than the non-pregnant uterus; this is not a pharmacokinetic difference but a receptor density and coupling efficiency change driven by estrogen.
Schiff PL. Ergot and its alkaloids. Am J Pharm Educ. 2006;70(5):98.
doi:10.5688/aj700598Lorenz N, Olsovska J, Sulc M, Tudzynski P. Alkaloid cluster gene ccsA of the ergot fungus Claviceps purpurea encodes chanoclavine I synthase, a flavin adenine dinucleotide-containing oxidoreductase mediating the transformation of N-methyl-dimethylallyltryptophan to chanoclavine I. Appl Environ Microbiol. 2010;76(6):1822–1830.
doi:10.1128/AEM.00737-09Boissier JR. General pharmacology of ergot alkaloids. Pharmacology. 1978;16(Suppl 1):12–26.
doi:10.1159/000136805Missale C, Nash SR, Robinson SW, Jaber M, Caron MG. Dopamine receptors: from structure to function. Physiol Rev. 1998;78(1):189–225.
doi:10.1152/physrev.1998.78.1.189Silberstein SD, McCrory DC. Ergotamine and dihydroergotamine: history, pharmacology, and efficacy. Headache. 2003;43(2):144–166.
doi:10.1046/j.1526-4610.2003.03034.xTfelt-Hansen P, Saxena PR, Dahlof C, et al. Ergotamine in the acute treatment of migraine: a review and European consensus. Brain. 2000;123(1):9–18.
doi:10.1093/brain/123.1.9de Groot AN, van Dongen PW, Vree TB, Hekster YA, van Roosmalen J. Ergot alkaloids. Current status and review of clinical pharmacology and therapeutic use compared with other oxytocics in obstetrics and gynaecology. Drugs. 1998;56(4):523–535.
doi:10.2165/00003495-199856040-00002American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 183: Postpartum Hemorrhage. Obstet Gynecol. 2017;130(4):e168–e186.
doi:10.1097/AOG.0000000000002351Aellig WH, Nuesch E. Comparative pharmacokinetic investigations with tritium-labelled ergot alkaloids after oral and intravenous administration in man. Int J Clin Pharmacol Biopharm. 1977;15(3):106–112.
Diener HC, Limmroth V. Medication-overuse headache: a worldwide problem. Lancet Neurol. 2004;3(8):475–483.
doi:10.1016/S1474-4422(04)00824-5